RecruitingPHASE1, PHASE2NCT07539441
A Study of Mirdametinib in People With Central Nervous System Tumors
Studying Central nervous system embryonal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Anna Piotrowski, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Mirdametinib(drug)
- Enrollment
- 26 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre, New York, United States
Collaborators
SpringWorks Therapeutics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07539441 on ClinicalTrials.govOther trials for Central nervous system embryonal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07198256AI-assisted Diagnosis of Malignant Brain TumorsSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1NCT05298995GD2-CAR T Cells for Pediatric Brain TumoursBambino Gesù Hospital and Research Institute
- ACTIVE NOT RECRUITINGPHASE1NCT05413304Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05588453Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the BrainKari Kendra
- RECRUITINGPHASE1NCT05293197Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric PatientsAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT05711992Rare Embryonal Tumors of the Central Nervous System: International RegistryImmune Oncology Research Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04074096Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisUNICANCER
- RECRUITINGNANCT04181684LITT Followed by Hypofractionated RT for Recurrent GliomasUniversity of Maryland, Baltimore